6 December 2024 - Merck's MET inhibitor Tepmetko (tepotinib) has been recognized by the national health insurance reviewer as eligible for health insurance coverage for the treatment of exon 14-deleted, locally advanced, or metastatic non-small cell lung cancer.

Also, GSK-Janssen's HIV drugs, Vocabria (cabotegravir) and Rekambys (rilpivirine) combination therapy, have been recognised for reimbursement appropriateness, moving one step closer to potential health insurance coverage.

Read Korea Biomedical Review article